Needham & Company LLC reissued their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Thursday, MarketBeat.com reports. They currently have a $110.00 price objective on the stock, up from their prior price objective of $95.00.
“Mesoblast announced good news that remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft- versus-host disease (GvHD).”,” Needham & Company LLC’s analyst commented.
NBIX has been the topic of several other reports. Robert W. Baird restated a buy rating and set a $84.00 price target on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Oppenheimer set a $95.00 price target on shares of Neurocrine Biosciences and gave the company a buy rating in a report on Monday, January 15th. Piper Jaffray Companies restated a buy rating and set a $76.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. Deutsche Bank reiterated a buy rating and issued a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Jefferies Group upped their price objective on shares of Neurocrine Biosciences to $105.00 and gave the stock a buy rating in a report on Friday, January 5th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $91.50.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.11). The firm had revenue of $94.52 million for the quarter, compared to analyst estimates of $94.00 million. During the same quarter in the prior year, the company posted ($0.51) EPS. sell-side analysts predict that Neurocrine Biosciences will post -0.19 earnings per share for the current year.
In other Neurocrine Biosciences news, Director Gary A. Lyons sold 5,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $84.67, for a total transaction of $423,350.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Haig P. Bozigian sold 1,625 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total transaction of $128,570.00. The disclosure for this sale can be found here. Insiders sold 342,950 shares of company stock valued at $27,037,226 over the last quarter. 4.80% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. First Trust Advisors LP lifted its position in Neurocrine Biosciences by 29.0% during the 3rd quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after acquiring an additional 176,136 shares during the last quarter. Janus Henderson Group PLC lifted its position in Neurocrine Biosciences by 2.6% during the 3rd quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after acquiring an additional 140,639 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Neurocrine Biosciences by 3.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 181,751 shares of the company’s stock worth $11,135,000 after acquiring an additional 5,554 shares during the last quarter. Chicago Equity Partners LLC acquired a new position in Neurocrine Biosciences during the 4th quarter worth $2,759,000. Finally, Moody Aldrich Partners LLC lifted its position in Neurocrine Biosciences by 13.2% during the 3rd quarter. Moody Aldrich Partners LLC now owns 22,256 shares of the company’s stock worth $1,364,000 after acquiring an additional 2,591 shares during the last quarter.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.